Clinical trials
Breast Ductal Carcinoma In Situ clinical trials
Below are recruiting breast ductal carcinoma in situ clinical trials, each written for real people, not researchers. We’re tracking 69 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07292246Recruiting
HandX-assisted endoscopic mastectomy study for breast cancer
This trial tests a new, less invasive way to remove breast tissue using a small camera (endoscope) with a device called HandX. It's for women who need a mastectomy for early-stage breast cancer, DCIS, or to reduce high risk, and aims to see if it's safe and works well.
Glyfada, AtticaAges 18 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Birmingham, AlabamaAges 18 years+ - NCT04913064Recruiting
White button mushroom supplement for inflammation in high-risk breast cancer
This trial tests whether a white button mushroom powder supplement can lower inflammation in postmenopausal women who have a high risk of breast cancer. If it helps, it could improve early prevention strategies for people at higher risk.
Duarte, CaliforniaAges 21 years+ - NCT05557877RecruitingPhase 2
Low-dose aspirin to prevent postpartum breast cancer
This study tests whether taking a low dose of aspirin after childbirth can lower the chance of developing breast cancer later. You may be asked to provide blood, urine, and breast tissue samples so researchers can look for changes that could explain why aspirin may help.
Scottsdale, ArizonaAges 18–45 - NCT06516289RecruitingPhase 2
Neoadjuvant treatment for BRCA-mutated HER2-negative breast cancer
This trial tests a combination of two oral medications (HRS-1167 and famitinib) with or without an immunotherapy drug (camrelizumab) before surgery for women with a BRCA gene mutation and HER2-negative breast cancer. It aims to see if these drugs can shrink tumors before surgery.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05786664Recruiting
Breast cancer survivor study collecting your health samples
This study invites women who finished treatment for non-metastatic invasive breast cancer to share health information and biological samples for future research. It may help scientists understand survivorship and improve care after treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT07454642RecruitingPhase 1
AVA6103 for advanced FAP-positive solid tumors
This trial tests a new drug called AVA6103 for certain advanced cancers that show a protein called FAP. It is for people who have already tried other treatments or cannot take them, and aims to see if the drug is safe and helps shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT06640881RecruitingPhase 2
Repeat breast-conserving surgery with partial reirradiation
This trial tests a new approach for women whose breast cancer has returned in the same breast after earlier surgery and radiation. Instead of removing the whole breast, doctors will remove only the tumor again and give a small, focused dose of radiation before surgery, aiming to preserve the breast.
AmsterdamAges 50 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Denver, ColoradoAges 18 years+ - NCT06042569RecruitingPhase 2
Lower-dose chemo for older women with HER2-negative breast cancer
This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.
Duarte, CaliforniaAges 65 years+ - NCT05451784RecruitingPhase 1/Phase 2
PD-1 TIL therapy for advanced triple-negative breast cancer
This study tests an immune-cell treatment made from your tumor tissue. It aims to help people with advanced or metastatic triple-negative breast cancer by collecting PD-1–positive immune cells and giving them back after treatment.
BarcelonaAges 18 years+ - NCT06557057Recruiting
Aromatase inhibitors and diabetes risk in breast cancer
This study looks at how aromatase inhibitors, a type of hormone therapy for breast cancer, affect blood sugar and diabetes risk. It compares women taking these drugs to those on tamoxifen or healthy women, to see if there are changes in glucose control.
Rochester, MinnesotaAges Any age - NCT03408353Recruiting
MERIT study uses mammogram and blood tests to assess breast cancer risk
This study looks for signs in blood samples and imaging that may help estimate breast cancer risk earlier. You would do a mammogram and give blood at the start and then again at yearly follow-up visits.
Houston, TexasAges 25–80 - NCT05288205RecruitingPhase 1/Phase 2
JAB-21822 plus JAB-3312 for KRAS G12C solid tumors
This Phase 1/2a trial tests two investigational pills (JAB-21822 and JAB-3312) in people with advanced solid cancers that have a KRAS G12C mutation. It’s for cases where standard treatments have failed or aren’t suitable, to see if the drugs can shrink tumors and improve outcomes.
Hefei, AnhuiAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Duarte, CaliforniaAges 18 years+ - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Gilbert, ArizonaAges 18 years+ - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70 - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT05799274RecruitingPhase 1
Safety study of a new PET imaging drug for cancers
This Phase 1 study tests how safe RAD301 is and how it behaves in the body when given for PET imaging in healthy volunteers and people with certain cancers. It may help doctors learn whether this imaging drug can clearly show cancer areas and be tolerated well.
Princeton, New JerseyAges 18 years+ - NCT06907095Recruiting
Early cancer detection study for high-risk individuals
This study tests if a simple blood or fluid test can find cancer early in people with a higher-than-average risk. If you have certain genetic mutations, a strong family history of cancer, or other high-risk conditions, you may be able to join.
VillejuifAges 18 years+
Hear when a new Breast Ductal Carcinoma In Situ trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast ductal carcinoma in situ?
- Yes. Clin2 currently lists 69 recruiting breast ductal carcinoma in situ studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast ductal carcinoma in situ trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast ductal carcinoma in situ trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.